AstraZeneca PLC (the "Company") today confirmed that the intended ratio change
to its NYSE-listed sponsored Level 2 American Depositary Receipt ("ADR")
programme announced on 26 June 2015 has now become effective. With effect from
27 July 2015, the Company's American Depositary Share ("ADS") ratio is two (2)
ADSs per one (1) Ordinary Share. The former ratio was one (1) ADS per one (1)
Ordinary Share. There are no changes to the underlying Ordinary Shares.
ADS holders at the close of business New York time on the record date, 22 July
2015, received a distribution of one additional ADS for every ADS held. No
action was required by ADS holders to effect this change.
Contact details for Citibank, N.A., the Company's ADR depositary, can be found
below.
A C N Kemp
Company Secretary
27 July 2015
CONTACT
Citibank Shareholder Services
PO Box 43077 Tel (toll free in the US): +1-888-697-8018
Providence Tel (outside the US): +1-781-575-4555
RI 02940-3077
US
Media Enquiries
Esra Erkal-Paler +44 20 7604 8030 (UK/Global)
Jacob Lund +46 8 553 260 20 (Sweden)
Michele Meixell + 1 302 885 6351 (US)
Investor Enquiries
UK
Thomas +44 20 7604 8199 mob: +44 7818 524185
Kudsk
Larsen
Eugenia Respiratory, Inflammation +44 20 7604 8233 mob: +44 7884 735627
Litz and Autoimmunity
Nick Cardiovascular andMetabolic +44 1763 263 994 mob: +44 7717 618834
Stone Disease
Karl Hård Oncology +44 20 7604 8123 mob: +44 7789 654364
Craig Infection, Neuroscience and +44 20 7604 8591 mob: +44 7881 615764
Marks Gastrointestinal Disease
Christer +44 20 7604 8126 mob: +44 7827 836825
Gruvris
US
Dial / 301-398-3251 866-381-7277
Toll-Free
Confirmation of Change in ADS Ratio
| Source: AstraZeneca PLC
Attachments
